Zoledronic Acid and Pamidronate May Be Associated With ONJ

"The U.S. Food and Drug Administration (FDA) and Novartis warned healthcare professionals via letter of osteonecrosis of the jaw (ONJ) associated with zoledronic acid (Zometa) and pamidronate disodium (Aredia) use, mainly in cancer patients who have received bisphosphonates as a component of their therapy, according to an alert sent today from MedWatch, the FDA's safety information and adverse event reporting program."